Navigation Links
Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
Date:5/28/2009

atic colorectal cancer," said Robert De Jager, M.D., chief medical officer of Poniard. "We are continuing to observe the study participants to obtain overall survival data, and expect those data later this year. The new PFS, tumor response and neurotoxicity data provide the rationale to consider additional trials to develop picoplatin as a preferred platinum for the treatment of metastatic colorectal cancer."

Analyst and Investor Briefing

Poniard will host an investor event in Orlando on Sunday, May 31, 2009. Presentations will begin promptly at 6:00 p.m. Eastern Time. The event will feature presentations and discussion with expert oncologists, including Richard Goldberg, M.D., of the University of North Carolina's Lineberger Comprehensive Cancer Center, William Oh, M.D., of Harvard Medical School, and David S. Ettinger, M.D., of the Kimmel Comprehensive Cancer Center at Johns Hopkins, in addition to members of Poniard's senior management team. The analyst meeting will also be simultaneously Webcast from Poniard's Web site at www.poniard.com and will remain available for 30 days following the live event.

About Colorectal Cancer

CRC is the third most common cancer in both American men and women, and the third leading cause of cancer death in the U.S. In 2008, an estimated 148,810 new cases of colon and rectal cancer were expected to be diagnosed in the U.S., with an estimated 49,960 deaths.(1) A FOLFOX-containing regimen is the current standard of care but is associated with a high incidence of neuropathy. Discontinuation of oxaliplatin from FOLFOX is recommended by the National Comprehensive Cancer Network (NCCN) Practice Guidelines in Oncology (v.2.2009) after three months of therapy or sooner if significant neurotoxicity (> Grade 3) occurs, with other drugs maintained until the time of tumor progression.

About Picoplatin

Picoplatin
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update
2. Poniard Pharmaceuticals to Present New Data from Phase 2 Clinical Trials of Picoplatin in Multiple Tumor Types at the 45th Annual Meeting of the American Society of Clinical Oncology
3. Poniard Completes Patient Enrollment Target in Phase 3 SPEAR Trial of Picoplatin in Small Cell Lung Cancer
4. Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update
5. Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin
6. Poniard Pharmaceuticals Announces Final Top-Line Results from Phase 1 Trial Demonstrating Positive Bioavailability with Oral Picoplatin
7. Poniard Announces Positive Efficacy and Safety Data From Phase 1 Trial of Picoplatin in Multiple Tumor Types Including Ovarian Cancer
8. Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer
9. Poniard Announces Positive First-Line Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in Patients with Metastatic Hormone Refractory Prostate Cancer
10. Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting
11. Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... , September 23, 2014 ... announces the appointment of Jarrod Longcor ... Longcor is responsible for structuring, negotiating and executing ... as well as providing management and strategic leadership ... the Executive leadership team. Mr Longcor ...
(Date:9/22/2014)... , September 23, 2014 , ... health authorities, increasing rigor for trial master file (TMF) ... industry,s largest TMF survey to date reveals an increase ... to provide auditors with remote access to their electronic ... owners surveyed in the Veeva 2014 Paperless ...
(Date:9/22/2014)... 22, 2014 Avanir Pharmaceuticals, Inc. (NASDAQ: ... to sell $200 million of its common stock in ... and BofA Merrill Lynch are acting as joint book-running ... a 30-day option to purchase additional shares of its ... in the offering are being sold by Avanir.  The ...
Breaking Medicine Technology:Avillion Appoints Jarrod Longcor as Chief Business Officer 2Remote eTMF Access to Double in 2015, Reveals Industry-wide Survey 2Remote eTMF Access to Double in 2015, Reveals Industry-wide Survey 3Remote eTMF Access to Double in 2015, Reveals Industry-wide Survey 4Avanir Pharmaceuticals Announces Proposed Public Offering of Common Stock 2Avanir Pharmaceuticals Announces Proposed Public Offering of Common Stock 3
... , ... a new market research report is available in ... - A US Market Review , ... medical adhesives and sealants is gaining preeminence in ...
... Cyberonics, Inc. (Nasdaq: CYBX ) today announced that Dan ... Officer, will present at the 21st Annual Piper Jaffray Health Care ... PM EST. The conference session and webcast will be audio ... will host a webcast of the presentation live and by replay ...
Cached Medicine Technology:Reportlinker Adds Medical Adhesives and Sealants - A US Market Review 2Reportlinker Adds Medical Adhesives and Sealants - A US Market Review 3Reportlinker Adds Medical Adhesives and Sealants - A US Market Review 4Reportlinker Adds Medical Adhesives and Sealants - A US Market Review 5Reportlinker Adds Medical Adhesives and Sealants - A US Market Review 6Cyberonics to Present at 21st Annual Piper Jaffray Health Care Conference 2
(Date:9/23/2014)... 2014 AmerisourceBergen’s Innomar Strategies, a ... is now providing U.S. manufacturers access to the ... center coupled with its fully-licensed wholesale and import ... historically been difficult for smaller and mid-tier healthcare ... As a result of these regulations and the ...
(Date:9/23/2014)... The print component of Mental Health is distributed within ... approximately 327,720 copies and an estimated readership of 688,212. ... social media strategy and across a network of top ... version of the campaign, visit http://mentalhealthnews.ca/ . , ... host of TSN’s Off the Record. Landsberg, who battles ...
(Date:9/23/2014)... 2014 Antibiotics revolutionized health care in the ... killed thousands of people. But bacteria are also ... bacteria are popping up more frequently. This week,s ... of new antibiotics and discusses the prospects for ... Why should you finish your pills if you ...
(Date:9/23/2014)... assumed about single parents, particularly single parents of young ... found that single parents of children younger than 5 ... without children -- and more so than single parents ... Behavior Among Single Parents of Young Children in the ... of Sex Research prior to appearing in print. ...
(Date:9/23/2014)... On September 23, 2014, My Positive Perspective founder Jason Deierlein ... the founder of Traveler of Charleston magazine and answered some ... At the start of the interview, Deierlein asked Simmons, “How ... replied by saying, “I had worked for the yellow pages ... and decided to start my own magazine thinking I could ...
Breaking Medicine News(10 mins):Health News:AmerisourceBergen Paves Path to Canadian Markets 2Health News:AmerisourceBergen Paves Path to Canadian Markets 3Health News:‘Sick, not weak’: Mediaplanet’s "Mental Health” Campaign Dispels Stigmas and Bolsters Support for the One in Five Canadians Suffering Mental Illness 2Health News:Kinsey study of single parents' dating, sexual activity contradicts assumptions 2Health News:My Positive Perspective Airs Episode With the Founder of Traveler of Charleston Magazine 2
... vaccine were ordered on the advice of the Chief Veterinary Officer ... ,The decision was taken after the organic free-range poultry producers requested ... the presence of bird flu and so assist its spread of ... vaccinating the poultry in advance of an avian influenza outbreak should ...
... Glasgow University have used technology developed for digital cameras ... of blindness//, age related macular degeneration and retinitis pigmentosa. ... Glasgow University's physics department, the objective of implanting such ... retina that could "fool" the brain into thinking that ...
... test have found that any kind of exercise will help ... Todd M. Manini, an exercise physiologist at the U.S. National ... saying that self-reported exercise like running or jogging is beneficial. ... a protective value." ,His research team conducted a ...
... of Parliament is to pass a law that would protect ... hospital, along with the right// for a woman with the ... before marriage. ,India is supposedly the country with ... in the world and this bill is being proposed to ...
... microbiology and molecular genetics, and his colleagues from Michigan State ... and potential for growing flu virus. , This is ... new human flu vaccines which is cheaper and produced in ... the new cell line while working on the Marek's disease ...
... A study by Temple University researchers has found that ... though they smoke less cigarettes than Caucasians. The study ... which confirms findings from a smaller preliminary study published ... the distribution of emphysema and the severity of lung ...
Cached Medicine News:Health News:Physical Activity of any kind to Prolong Life 2Health News:New Law On HIV/AIDS To Be Implemented At The Monsoon Session Of Parliament 2Health News:New Cell Lines Cuts Down the Cost and Time in the Production of Flu Vaccine 2Health News:African Americans Have Increased Risk Of Emphysema 2
... GE Healthcare is ... in best-in-class analysis programs ... area monitoring device. With ... 12SL, Gender-Specific, and ACI-TIPI, ...
... The Affinity pacemaker family ... smallest, truly automatic devices. ... combination of advanced technologies ... DR pacemaker incorporates the ...
... small bench top chemistry analyzer that utilizes dry ... with results available within 8 - 15 minutes. ... instrument accepts whole blood samples and is calibrated ... At the conclusion of testing, results are available ...
... is a battery-backed up, microprocessor based, quality instrument ... It stores and displays a chart on its ... scrolled through or zoomed into and out of, ... to 3 months can be seen at one ...
Medicine Products: